30 July 2013

US court rules Teva patent invalid

A US court has ruled that an Israeli company’s patent for a multiple sclerosis (MS) drug is invalid, paving the way for rivals to market a generic version.

In a ruling at the US Court of Appeals for the Federal Circuit on Friday, July 26, Teva Pharmaceuticals was told one of its patents protecting the Copaxone drug was invalid. The patent in question was due to expire in 2015; other patents at issue were upheld by the court, but these expire in 2014.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Boehringer and Dr Reddy’s spar over plausibility as trial wraps up

15 October 2026 A dispute over missing experimental data and patent disclosures draws to a close as Boehringer and Dr Reddy’s deliver their final arguments. The court’s decision could bring greater clarity to the UK approach to plausibility and determine whether Dr Reddy’s can move ahead with its proposed generic launch.

Careers

Haynes Boone expands in California with new office

14 October 2026 Growing demand from life sciences and healthcare clients prompts an expansion in California, bringing the firm closer to biotechnology companies, research institutions and key courts for its Southern California litigators.

Pharma

Accord’s generic hopes dashed in cyanide antidote ruling

14 October 2026 Efforts to bring a generic cyanide poisoning treatment to market have suffered a setback after a US judge rejected challenges to three patents and criticised the drugmaker’s interpretation of the treatment’s chemical composition.